1Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology,2003, 38: 545-553.
2Perelson AS, Ribeiro RM. Hepatitis B virus linetics and mathematical modeling. Semin Liver Dis, 2004, 24(Suppl 1): 11-16.
3Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol, 2003, 77: 68-76.
4Perrillo RP. Overview of treatment of hepatitis B: key approaches and clinical challenges. Semin Liver Dis, 2004, 24(Suppl 1): 23-29.
5Wright TL. Clinical trial results and treatment resistance with Lamivudine for hepatitis B. Semin Liver Dis, 2004, 24(Suppl 1): 31-36.
6Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis, 2004, 24(Suppl 1): 3-10.
7Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology,2003, 125: 1714-1722.
8Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther, 2004,
9: 257-262.9.Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 2003, 348: 808-816.
10Westland CE, Yang H, Delaney WE, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology, 2003, 38: 96-103.
